Dallas, Texas 08/21/2014 (FINANCIALSTRENDS) – Nuvilex Inc (OTCMKTS:NVLX) the cancer therapy-researcher and developer has in an announcement notified the commencement of pre-clinical studies at the Transitional Drug Development, for its flagship cancer treatment. The pre-clinical tests will establish if Nuvilex’s drug can stem the accumulation of fluid – malignant ascites – in the regions of the abdomen, the characteristic region in the case of tumor of the abdomen.
Nuvilex Inc (OTCMKTS:NVLX) which operates from its Sliver Spring offices in the US has been driving technology changes and innovation in the biotechnology field. It specializes in life technology and has been successful in building living-cell encapsulation.
CEO Says Its Banner Day For Nuvilex
Chief Operating Officer and President of Nuvilex, Kenneth Waggoner reported that, “The start of these studies at TD2 is a banner day for Nuvilex. We are extremely gratified to have a prestigious organization such as TD2 performing these studies on our behalf. “
The CEO added further that, the studies using “Cell-in-a-Box® cellulose-based live cell encapsulation technology” will be the first ever of this kind. He also noted that the malignant ascites fluid in the abdomen is the ‘seed’ which causes the new tumor.
The main effect of such fluid accumulation is high degree of ill ease in such patients. The only cure currently for such patients is the removal of the malignant ascites fluid from the cancer patient’s abdomen at regular intervals.
Nuvilex Inc (OTCMKTS:NVLX) current studies includes mice, where TD2 uses such mice which have no immune system. The mice will then be studied for their humane end points. As Waggoner stated, “We are confident that this work at TD2 will prove to be just the beginning of a long and fruitful journey for Nuvilex as we strive to develop our unique cancer treatment.”